A new commentary in the International Journal of Obesity is drawing attention to a rapidly emerging problem in modern obesity care: stigma directed not only at people’s bodies, but also at the medications they use to manage weight. As glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 medications, have moved from specialist clinics into mainstream public conversation, they have become symbols in a wider cultural debate about discipline, self-control and what counts as a “legitimate” way to lose weight. The commentary argues that these attitudes may create a distinct form of treatment-related stigma, with consequences for patients’ mental health, physical health and willingness to begin or continue therapy.
GLP-1 receptor agonists were initially developed to treat type 2 diabetes, but their effects on appetite regulation and body weight have transformed the treatment landscape for obesity. These drugs mimic or enhance the action of GLP-1, a hormone released by the intestine after eating. GLP-1 signaling acts on pancreatic cells to improve glucose-dependent insulin secretion and reduce inappropriate glucagon release. It also influences brain regions involved in appetite and reward, while slowing gastric emptying, particularly during the early phase of treatment. Together, these effects can reduce hunger, increase feelings of fullness and support clinically meaningful weight loss for many patients. The medications, however, do not eliminate the biological complexity of obesity, which is influenced by genetics, metabolism, neurobiology, environment and social conditions.
Despite the medical evidence supporting their use, GLP-1 therapies are frequently described in public discussions as a shortcut. Critics often contrast medication-assisted weight loss with diet and exercise, implying that individuals who use pharmacological treatment have avoided the “hard work” required to change their bodies. This framing reflects an older moral narrative in which body weight is treated as a visible measure of personal discipline. According to this view, weight loss is considered more deserving when it results from restraint, exercise or sustained lifestyle modification, while medication is portrayed as an easier, less authentic or less morally valuable alternative. The commentary by S. M. Post emphasizes that such judgments can stigmatize treatment even when the medication is prescribed within accepted medical guidelines.
Traditional weight stigma refers to negative stereotypes, prejudice and discrimination directed at people because of their body size or weight. It can appear in healthcare, employment, education, media representation and personal relationships. Research has linked weight stigma with psychological distress, depression, anxiety, disordered eating, avoidance of medical care and physiological stress responses. Importantly, stigma can also undermine health behaviors. People who feel judged may delay appointments, disengage from physical activity in public spaces or avoid discussing weight-related concerns with clinicians. These effects demonstrate that stigma is not merely an interpersonal insult or a matter of language; it can become a structural and biological health risk.
GLP-1-related stigma may overlap with weight stigma while adding a separate layer of judgment. A person using a GLP-1 medication may be evaluated not only on the basis of body size, but also on whether their method of treatment is seen as legitimate, courageous or morally acceptable. Someone may be told that medication is “cheating,” that weight loss achieved with treatment does not count or that the person should rely exclusively on willpower. These messages can produce a complicated form of identity threat. Individuals may feel pressure to conceal their prescriptions, minimize their treatment or defend their decision to use a medication that has been medically recommended. For people who have experienced weight stigma already, treatment-related criticism may reinforce the belief that no approach will be considered acceptable.
The distinction matters because the two forms of stigma may operate through different psychological and behavioral pathways. Weight stigma focuses primarily on the person’s body and the assumptions attached to it. GLP-1-related stigma focuses on the intervention and the perceived moral meaning of receiving medical assistance. A patient can therefore encounter both at once: criticism for having obesity and criticism for using treatment to address it. This combined pressure could influence medication initiation, adherence and persistence. Patients who anticipate ridicule may avoid asking about GLP-1 therapy, while those already taking it may skip doses, stop treatment prematurely or avoid revealing side effects. Such decisions could reduce the clinical benefits of therapy and make it more difficult for clinicians to monitor safety and effectiveness.
The emerging issue also raises technical questions for researchers. Existing weight-stigma scales may measure beliefs about body size, stereotypes about laziness or judgments about personal responsibility, but they may not capture perceptions of medication-assisted weight management. New instruments may need to assess whether people view GLP-1 treatment as medically legitimate, whether they believe users deserve less credit for weight loss and whether they expect social rejection after disclosing treatment. Researchers will also need to determine how these attitudes differ across groups, including people currently using GLP-1 medications, those considering them and those who have stopped treatment. Psychometric studies could examine reliability, construct validity and measurement invariance to establish whether a proposed scale measures the same phenomenon across genders, age groups, racial and ethnic populations, body sizes and healthcare settings.
Clarifying the concept could improve both clinical communication and public health messaging. Clinicians may need to discuss not only expected benefits and adverse effects, such as gastrointestinal symptoms, but also the social pressures that can affect treatment decisions. A patient who is reluctant to use medication may not be rejecting medical care itself; they may be responding to messages that frame pharmacological assistance as a moral failure. Conversely, a patient who stops treatment may be experiencing shame, fear of disclosure or unrealistic expectations about maintaining weight loss after discontinuation. Supportive counseling can make clear that obesity is a chronic, biologically regulated disease and that medication is one evidence-based tool among several, rather than a replacement for comprehensive care or a test of personal virtue.
The commentary arrives as public interest in GLP-1 medications continues to expand faster than scientific understanding of their social consequences. Media coverage often focuses on dramatic transformations, celebrity use, shortages and disputes over access, while giving less attention to the emotional experience of patients navigating treatment decisions. Post’s call for conceptual clarity encourages researchers in obesity medicine, behavioral science and psychosocial health to investigate how treatment-related stigma develops, how it is communicated and how strongly it affects outcomes. Understanding the difference between stigma directed at body weight and stigma directed at the use of medication could help researchers design better surveys, clinicians provide more patient-centered care and health systems reduce barriers to treatment. The central question is no longer only whether GLP-1 therapies can change weight and metabolic health, but also whether society will allow people to use them without demanding that effective medical care first pass a moral test.
Subject of Research: GLP-1-related treatment stigma and its relationship to weight stigma, mental health, physical health and engagement with obesity treatment.
Article Title: GLP-1 receptor agonists and the emergence of treatment-related stigma: a call for conceptual clarity
Article References: Post, S.M. “GLP-1 receptor agonists and the emergence of treatment-related stigma: a call for conceptual clarity.” International Journal of Obesity (2026). https://doi.org/10.1038/s41366-026-02200-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41366-026-02200-5
Keywords: GLP-1 receptor agonists, obesity, weight stigma, treatment-related stigma, obesity treatment, mental health, medication adherence, healthcare, public health, psychometrics
